CYP2C8 and depressive disorder: NOC3L eQTLs in the cerebellum and nucleus accumbens have previously been demonstrated to associate with depression severity and antidepressant response (Kanders et al., 2020), and one of the substrates of CYP2C8 is clinically prescribed as treatment for major depressive disorder (phenelzine; Q. Wang et al., 2019).